Health
Second dose of Pfizer-BioNTech COVID-19 vaccine may not benefit previously infected individuals – News-Medical.Net
Researchers at the NYU Grossman School of Medicine have shown that a second dose of the Pfizer-BioNTech BNT162b2 vaccine may not offer any additional protection…
Researchers at the NYU Grossman School of Medicine have shown that a second dose of the Pfizer-BioNTech BNT162b2 vaccine may not offer any additional protection against coronavirus disease 2019 (COVID-19) over one dose among individuals previously infected with the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
In a study evaluating immune responses to the Pfizer-BioNTech vaccine, Ramin Herati and colleagues observed robust humoral (antibody) responses following two…
-
General18 hours agoVictorian school teacher charged with soliciting child abuse material
-
General9 hours agoAustralia loses ODI series to South Africa with defeat in second game in Mackay
-
Noosa News24 hours agoBrisbane news LIVE updates: University gains Olympic scholarships
-
Business21 hours agoEconomic roundtable or maturity test?